Previous studies have demonstrated that talazoparib can able to trap PARP on chromatin, leading to induction of replication stress in cancer cells.[47, 48] In this regard, our result showed that talazoparib induced PARP trapping was further enhanced in the presence of DHS (Figure S40, Supporting Information), suggesting higher replication stress (Figure 6F–I) in combination treatment may be partly attributable to enhanced PARP trapping on chromatin. Here, PARP1 is linked to cancer.